Skip to content
Jay Vadakekolathu

Jayakumar Vadakekolathu

Associate Professor

School of Science & Technology

Staff Group(s)
Bioscience

Role

Dr Jayakumar Vadakekolathu is an Associate Professor and leads the Spatial and Single-Cell Multi-Omics Facility at the John van Geest Cancer Research Centre, Nottingham Trent University, UK. His research focuses on cancer immunology, biomarker discovery, and translational oncology, with a particular emphasis on understanding how tumour, immune, and stromal cells interact within the tumour microenvironment to influence disease progression and treatment response. Using advanced spatial and single-cell technologies, including NanoString GeoMx Digital Spatial Profiling and the 10x Genomics Xenium, Visium, and Chromium platforms, his work investigates the cellular and molecular architecture of cancer at high resolution. By integrating spatial transcriptomics, single-cell genomics, bulk RNA sequencing, and proteomics, he generates multi-omics datasets that help uncover mechanisms of tumour evolution, immune escape, and treatment resistance. Over the past decade, Dr Vadakekolathu has established a strong track record in translational cancer research, publishing in leading journals and presenting at major scientific conferences worldwide. He collaborates extensively with academic, clinical, pharmaceutical, and biotechnology partners across the UK, Europe, and the United States. His research has contributed to the molecular characterisation of clinical trial cohorts, the discovery of novel biomarkers, and the development of precision oncology approaches. His overarching goal is to translate multi-omics discoveries into clinically meaningful advances that improve patient outcomes and support the wider implementation of personalised cancer medicine.

Career overview

Dr Jayakumar Vadakekolathu obtained an MSc in Biotechnology from Bharathidasan University, Tiruchirappalli, India. Following his Master's degree, he worked as a Senior Research Fellow at the Indian Institute of Spices Research (IISR), Calicut, Kerala, for five years. He then pursued an MRes in Advanced Genomics and Proteomics Sciences (AGPS), a joint programme offered by the University of Nottingham and Nottingham Trent University. He subsequently completed his PhD in Cancer Immunology at Nottingham Trent University under the supervision of Professor Robert C. Rees. Since completing his PhD, Dr Vadakekolathu has been a member of the John van Geest Cancer Research Centre, contributing to a range of research projects led by Professor Robert C. Rees, Professor Graham Pockley, and Professor Sergio Rutella before establishing his own independent research group.

Research areas

Immune Escape and Response to Immunotherapy in Leukaemia

Dr Jayakumar Vadakekolathu's research focuses on understanding why immunotherapies achieve durable responses in some patients with acute myeloid leukaemia (AML) while proving ineffective in others. Working with Professor Sergio Rutella, he developed and validated immune gene signatures that predict patient survival and therapeutic response across large international cohorts. Through integrated multi-omics approaches, his research has revealed how genetic alterations, particularly TP53 mutations, reshape the immune landscape of AML and drive resistance to immune-mediated killing. These studies have identified key pathways that enable leukaemia cells to evade T-cell attack and have provided important insights into mechanisms of immune escape. He has also contributed extensively to the field through reviews of immune evasion mechanisms and T-cell-directed immunotherapies in AML.

Spatial Biology and Single-Cell Analysis of Tissue Ecosystems

A major focus of Dr Vadakekolathu's research is the application of spatial and single-cell technologies to investigate cellular organisation and function within complex tissue environments. His group combines bulk transcriptomics, single-cell sequencing, spatial transcriptomics, and proteomics to characterise the location, identity, and activity of individual cells within their native microenvironment. His studies have identified spatial patterns of T-cell dysfunction in TP53-mutated AML and uncovered critical interactions between stromal, tumour, and immune cells in triple-negative breast cancer. Through interdisciplinary collaborations, his research has also advanced understanding of early fibrotic processes in systemic sclerosis, immune dysregulation in type 1 diabetes, and the cellular architecture of the human colon.

Tumour Microenvironment and Cancer Progression

Dr Vadakekolathu investigates how interactions between tumour cells, stromal populations, and immune cells influence cancer initiation, progression, and response to therapy. In breast cancer, his work has identified epigenetic regulators, including protein methyltransferases, that shape the tumour microenvironment and immune contexture. Activation of these pathways by inflammatory cytokines such as IFN-γ, TNF-α, and IL-6 has been associated with poor clinical outcomes, and his group is exploring therapeutic strategies to target these mechanisms. His broader research interests encompass the molecular drivers of tumour invasion and metastasis in breast cancer, epithelial-mesenchymal transition in prostate cancer, and the development of innovative immunotherapeutic approaches for solid tumours.

Next-Generation Cellular Immunotherapies

Building on discoveries in tumour immunology and immune resistance, Dr Vadakekolathu's research programme develops and evaluates next-generation cellular immunotherapies for cancer. Current work focuses on defining the mechanisms of action of engineered natural killer (NK) cell therapies and identifying strategies to improve their clinical efficacy. His group is also developing gene-edited T-cell and NK-cell platforms designed to overcome tumour-mediated immune suppression and enhance anti-tumour activity. Through these studies, the laboratory aims to accelerate the translation of innovative cellular therapies into effective treatments for both haematological malignancies and solid tumours.

Vadakekolathu welcomes enquiries from prospective PhD students, clinical collaborators, and industry partners interested in cancer immunology, spatial and single cell biology, multi-omics technologies, biomarker discovery, and cellular immunotherapy.

Publications

Peer-reviewed research papers

  1. Dalleywater W, Predeus AV, Cakir B, Mazin P, Vadakekolathu J, Rutella S, et al. Generation of biologically responsive colon-like intestinal tissue patches from human induced pluripotent stem cells using a rapid co-differentiation platform. Stem Cell Res Ther. 2026;17(1):182. doi:10.1186/s13287-026-05006-4
  2. Alhamar G, Fallucca S, Richardson SJ, Torabi F, Christie MR, Vadakekolathu J, et al. Raised levels of interleukin-8 and myeloperoxidase in patients with recent onset type 1 diabetes. Diabetes Obes Metab. 2025;27(11):6491-8. doi:10.1111/dom.70048
  3. Tin E, Rutella S, Khatri I, Na Y, Yan Y, MacLean N, Vadakekolathu J, et al. SOCS1 protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity. Blood Cancer Discov. 2025;6(3):217-32. doi:10.1158/2643-3230.BCD-24-0140
  4. Hatziapostolou M, Koutsioumpa M, Zaitoun AM, Polytarchou C, Edderkaoui M, Mahurkar-Joshi S, Vadakekolathu J, et al. Promoter methylation leads to hepatocyte nuclear factor 4A loss and pancreatic cancer aggressiveness. Gastro Hep Adv. 2024;3(5):687-702. doi:10.1016/j.gastha.2024.04.005
  5. Ocadlikova D, Lussana F, Fracchiolla N, Bonifacio M, Santoro L, Delia M, …, Vadakekolathu J, et al. Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: a Campus ALL study. Br J Haematol. 2023;203(4):637-50. doi:10.1111/bjh.19104
  6. Torabi F, Vadakekolathu J, Wyatt R, Leete P, Tombs MA, Richardson CC, et al. Differential expression of genes controlling lymphocyte differentiation and migration in two distinct endotypes of type 1 diabetes. Diabet Med. 2023;40(9):e15155. doi:10.1111/dme.15155
  7. Atobatele AG, Tonoli E, Vadakekolathu J, Savoca MP, Barr M, Kataria Y, et al. Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines. Cell Death Dis. 2023;14(5):317. doi:10.1038/s41419-023-05818-9
  8. Luce A, Lombardi A, Ferri C, Zappavigna S, Tathode MS, Miles AK, …, Vadakekolathu J, et al. A proteomic approach reveals that miR-423-5p modulates glucidic and amino acid metabolism in prostate cancer cells. Int J Mol Sci. 2023;24(1):617. doi:10.3390/ijms24010617
  9. Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R, et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022;132(21):e159579. doi:10.1172/JCI159579
  10. Vadakekolathu J, Boocock DJ, Pandey K, Guinn BA, Legrand A, Miles AK, et al. Multi-omic analysis of two common P53 mutations: proteins regulated by mutated P53 as potential targets for immunotherapy. Cancers (Basel). 2022;14(16):3975. doi:10.3390/cancers14163975
  11. Corradi G, Bassani B, Simonetti G, Sangaletti S, Vadakekolathu J, Fontana MC, et al. Release of IFNγ by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. Clin Cancer Res. 2022;28(14):3141-55. doi:10.1158/1078-0432.CCR-21-3594
  12. Le Vu P, Vadakekolathu J, Idri S, Nicholls H, Cavaignac M, Reeder S, et al. A mutated prostatic acid phosphatase (PAP) peptide-based vaccine induces PAP-specific CD8+ T cells with ex vivo cytotoxic capacities in HHDII/DR1 transgenic mice. Cancers (Basel). 2022;14(8):1970. doi:10.3390/cancers14081970
  13. Howard FHN, Al-Janabi H, Patel P, Cox K, Smith E, Vadakekolathu J, et al. Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV-1 virus. Small. 2022;18(13):e2104763. doi:10.1002/smll.202104763
  14. Yau TO, Vadakekolathu J, Foulds GA, Du G, Dickins B, Polytarchou C, et al. Hyperactive neutrophil chemotaxis contributes to anti-tumor necrosis factor-α treatment resistance in inflammatory bowel disease. J Gastroenterol Hepatol. 2022;37(3):531-41. doi:10.1111/jgh.15764
  15. Ferri C, Di Biase A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, …, Vadakekolathu J, et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. J Exp Clin Cancer Res. 2022;41(1):20. doi:10.1186/s13046-021-02233-w
  16. Ragaini S, Wagner S, Marconi G, Parisi S, Sartor C, Nanni J, …, Vadakekolathu J, et al. An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia. Blood Adv. 2022;6(1):87-99. doi:10.1182/bloodadvances.2021004878
  17. Manjunath HS, Al Khulaifi M, Sidahmed H, Ammar A, Vadakekolathu J, Rutella S, et al. Gene expression profiling of FFPE samples: a titration test. Technol Cancer Res Treat. 2022;21:15330338221129710. doi:10.1177/15330338221129710
  18. Tulotta C, Lefley DV, Moore CK, Amariutei AE, Spicer-Hadlington AR, Quayle LA, …, Vadakekolathu J, et al. IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. NPJ Breast Cancer. 2021;7(1):95. doi:10.1038/s41523-021-00305-w
  19. Almshayakhchi R, Nagarajan D, Vadakekolathu J, Guinn BA, Reeder S, Brentville V, et al. A novel HAGE/WT1-ImmunoBody® vaccine combination enhances anti-tumour responses when compared to either vaccine alone. Front Oncol. 2021;11:636977. doi:10.3389/fonc.2021.636977
  20. Zhou Q, Vadakekolathu J, Watad A, Sharif K, Russell T, Rowe H, et al. SARS-CoV-2 infection induces psoriatic arthritis flares and enthesis resident plasmacytoid dendritic cell type-1 interferon inhibition by JAK antagonism offer novel spondyloarthritis pathogenesis insights. Front Immunol. 2021;12:635018. doi:10.3389/fimmu.2021.635018
  21. Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, …, Vadakekolathu J, et al. Macrophages mediate the antitumor effects of the oncolytic virus HSV1716 in mammary tumors. Mol Cancer Ther. 2021;20(3):589-601. doi:10.1158/1535-7163.MCT-20-0748
  22. Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, …, Vadakekolathu J, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751-62. doi:10.1182/blood.2020007732
  23. Vadakekolathu J, Lai C, Reeder S, Church SE, Hood T, Lourdusamy A, et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv. 2020;4(20):5011-24. doi:10.1182/bloodadvances.2020002512
  24. Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020;12(546):eaaz0463. doi:10.1126/scitranslmed.aaz0463
  25. Alves R, McArdle SEB, Vadakekolathu J, Gonçalves AC, Freitas-Tavares P, Pereira A, et al. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α. J Transl Med. 2020;18(1):2. doi:10.1186/s12967-019-02194-x
  26. Al-Juboori SIK, Vadakekolathu J, Idri S, Wagner S, Zafeiris D, Pearson JRD, et al. PYK2 promotes HER2-positive breast cancer invasion. J Exp Clin Cancer Res. 2019;38(1):210. doi:10.1186/s13046-019-1221-0
  27. Wagner S, Vadakekolathu J, Tasian SK, Altmann H, Bornhäuser M, Pockley AG, et al. A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. Blood Adv. 2019;3(8):1330-46. doi:10.1182/bloodadvances.2018030726
  28. Foulds GA, Vadakekolathu J, Abdel-Fatah TMA, Nagarajan D, Reeder S, Johnson C, et al. Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Front Immunol. 2018;9:2028. doi:10.3389/fimmu.2018.02028
  29. Vadakekolathu J, Al-Juboori SIK, Johnson C, Schneider A, Buczek ME, Di Biase A, et al. MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer. Cell Death Dis. 2018;9(3):344. doi:10.1038/s41419-018-0364-9
  30. Balahmar RM, Boocock DJ, Coveney C, Ray S, Vadakekolathu J, Regad T, et al. Identification and characterisation of NANOG+/OCT-4high/SOX2+ doxorubicin-resistant stem-like cells from transformed trophoblastic cell lines. Oncotarget. 2018;9(6):7054-65. doi:10.18632/oncotarget.24151
  31. Harner-Foreman N, Vadakekolathu J, Laversin SA, Mathieu MG, Reeder S, Pockley AG, et al. A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics. Sci Rep. 2017;7:40633. doi:10.1038/srep40633
  32. Saif JMS, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, et al. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. Eur J Immunol. 2014;44(4):994-1004. doi:10.1002/eji.201343863
  33. Sinoj J, Sheeja TE, Suseela Bhai R, Suraby EJ, Minoo D, Soji J, Jayakumar VN, et al. Somatic embryogenesis and transgenic development in black pepper for delayed infection and decreased spread of foot rot caused by Phytophthora capsici. J Plant Crops. 2014;42(1):20-8.
  34. Nirmal Babu K, Jayakumar VN, Divakaran M, Venugopal MN, Sudarshan MR, Radhakrishnan VV, et al. Genetic diversity and phylogenetic relationships among small cardamom (Elettaria cardamomum Maton.) cultivars and related genera using DNA markers. Int J Innov Hortic. 2012;1(1):47-56.
  35. Minoo D, Jayakumar VN, Veena SS, Vimala J, Basha A, Saji KV, et al. Genetic variations and interrelationships in Vanilla planifolia and few related species as expressed by RAPD polymorphism. Genet Resour Crop Evol. 2008;55(3):459-70. doi:10.1007/s10722-007-9252-3

Reviews and meeting reports

  1. Vadakekolathu J, Rutella S. Escape from T-cell-targeting immunotherapies in acute myeloid leukemia. Blood. 2024;143(26):2689-700. doi:10.1182/blood.2023019961
  2. Zafeiris D, Vadakekolathu J, Wagner S, Pockley AG, Ball GR, Rutella S. Discovery and application of immune biomarkers for hematological malignancies. Expert Rev Mol Diagn. 2017;17(11):983-1000. doi:10.1080/14737159.2017.1381560
  3. Vadakekolathu J, Rutella S. T-cell manipulation strategies to prevent graft-versus-host disease in haploidentical stem cell transplantation. Biomedicines. 2017;5(2):33. doi:10.3390/biomedicines5020033
  4. Malhi SK, Saif J, Vadakekolathu JN. The Twelfth International Conference on Progress in Vaccination Against Cancer (PIVAC 12), Nottingham, UK, 11-13 September 2012: insights into the dynamics of anti-tumour immunity and the development of cancer vaccines. Cancer Immunol Immunother. 2013;62(8):1431-7. doi:10.1007/s00262-013-1440-8 (Conference report)

Book chapters

  1. Vadakekolathu J, Miles AK, Boocock DJ, McArdle SEB. Identification of tumor antigens for clinical evaluation. In: [Editor(s), editors]. Tumor immunology and immunotherapy. Oxford: Oxford University Press; 2014. p. 127-9. doi:10.1093/med/9780199676866.003.0009 (NTU repository record)

Conference abstracts

  1. Bamigbola IE, Vadakekolathu J, Di Donato S, Kakkar V, Mulipa P, Ross R, et al. OP0215 Spatial transcriptomics of skin biopsies from very early systemic sclerosis unveils early drivers of skin fibrosis within the epidermis [abstract]. Ann Rheum Dis. 2025;84(Suppl 1):179.
  2. Skuli S, Vadakekolathu J, Fenu E, Bennett K, Palma J, Harris J, et al. Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML [abstract]. Blood. 2025;146(Suppl 1):1734.
  3. Nanni J, Vadakekolathu J, Bandini L, Ciciarello M, Volkava K, Bruno S, et al. T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia [abstract]. Blood. 2024;144(Suppl 1):2916.
  4. Mahajan N, Arthur L, Vadakekolathu J, Muth J, Davidson-Moncada JK, Rutella S. Single-Cell Transcriptional Landscape of W-NK1, an Off-the-Shelf Natural Killer Cell Therapy [abstract]. Blood. 2024;144(Suppl 1):7184.
  5. Vadakekolathu J, Skuli S, Boocock DJ, Coveney C, Ikpo EG, Wang B, et al. Multi-omic analyses of TP53-mutated acute myeloid leukemia identify prognostic metabolic signatures [abstract]. Blood. 2024;144(Suppl 1):2911.
  6. Leedom T, Muz B, Magee K, Vadakekolathu J, Arthur L, Tran M, et al. W-NK1 choreographs innate and adaptive immune responses to provide a robust and durable anti-AML response [abstract]. Blood. 2024;144(Suppl 1):916.
  7. Muth J, Leedom T, Hamil A, Luukkonen L, Tumala B, Carter A, …, Vadakekolathu J, et al. WU-NK-101, an enhanced memory natural killer (NK) cell therapy, with cetuximab (Ctx) for the treatment of advanced colorectal cancer (CRC) [abstract]. J Clin Oncol. 2023;41(4 Suppl):170.
  8. Rutella S, Cashen A, Muth J, Vadakekolathu J, Arthur L, Mahajan N, et al. S129: Adoptively infused memory-like (ML) natural killer (NK) cells elicit adaptive immune responses in patients with acute myeloid leukemia (AML) [abstract]. HemaSphere. 2023;7(Suppl):e4299744.
  9. Rutella S, Muth J, Vadakekolathu J, Leedom T, Hamil A, Arthur L, et al. WU-NK-101 (W-NK), a memory-like (ML) NK cell, intrinsically overcomes factors restricting adoptive cell therapy (ACT) in acute myeloid leukemia (AML) [abstract]. Blood. 2023;142(Suppl 1):466.
  10. Rutella S, Vadakekolathu J, Cashen AF, Mahajan N, Ruiz-Heredia Y, Martín-Muñoz A, et al. Adoptively infused memory-like natural killer cells impact adaptive immune responses in patients with acute myeloid leukemia [abstract]. Blood. 2023;142(Suppl 1):4813.
  11. Nanni J, Vadakekolathu J, Bandini L, Bruno S, Zannoni L, Sartor C, et al. T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3-Mutated Acute Myeloid Leukemia [abstract]. [Journal/meeting to confirm; probably Blood. 2023;142(Suppl 1)].
  12. Vadakekolathu J, Altmann H, Wobus M, von Bonin M, Schmitz M, Baretton GB, et al. Spatially resolved transcriptomics unveils unique T-cell dysfunctional states and prognostic gene expression signatures in TP53-mutated acute myeloid leukemia [abstract]. Blood. 2023;142(Suppl 1):291.
  13. Bhatnagar N, Petit V, Vadakekolathu J, Pinset C, Mahajan N, Dean J, et al. WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency [abstract]. Blood. 2023;142(Suppl 1):4834.
  14. Dalleywater W, Vadakekolathu J, Bills A, Rutella S, Ilyas M. Spatial Profiling of Human Colonic Crypt Demonstrates Cell Populations and their Niches in Unprecedented Detail [abstract]. J Pathol. 2023;261(Suppl 1):S22.
  15. Leedom TA, Muz B, Vadakekolathu J, Muth JJ, Li XH, Watson G, et al. WU-NK-101 as salvage therapy post immune checkpoint blockade (ICB) [abstract]. Cancer Res. 2023;83(7 Suppl):6418.
  16. Abdel-Fatah TM, Ball G, Chen X, Mehaisi D, Giannotti E, Auer D, Vadakekolathu J, et al. Abstract P1-08-19: Utilising artificial intelligence (AI) for analysing multiplex genomic and magnetic resonance imaging (MRI) data to develop multimodality predictive system for personalised neoadjuvant treatment of breast cancer (BC) [abstract]. Cancer Res. 2022;82(4 Suppl):P1-08-19.
  17. Corradi G, Bassani B, Simonetti G, Sangaletti S, Vadakekolathu J, Pazzaglia M, et al. Interferon-gamma-dependent IDO1 up-regulation in the bone marrow microenvironment is associated with increased T regulatory cells and worse clinical outcomes in acute myeloid leukemia patients [abstract]. Haematologica. 2022;107(Suppl):21-2.
  18. Muth JJ, Mathyer ME, Cruz B, DuFour C, Leedom T, Hamil AS, …, Vadakekolathu J, et al. P1426: WU-NK-101, an allogeneic memory NK cell, for the treatment of relapse or refractory (R/R) acute myeloid leukemia (AML) [abstract]. HemaSphere. 2022;6(Suppl):1309-10.
  19. Rutella S, Cashen AF, Muth J, Mathyer ME, Carter AJ, Tumala B, …, Vadakekolathu J, et al. Putative predictors of response to WU-NK-101, an allogeneic, enhanced memory (ML) natural killer (NK) cell therapy product, for relapsed/refractory (R/R) acute myeloid leukemia (AML) [abstract]. Blood. 2022;140(Suppl 1):3294.
  20. Rutella S, Vadakekolathu J, Hood T, Reeder S, Warren SE, Danaher P, et al. Abstract B63: Immune gene expression profiling of acute myeloid leukemia identifies predictors of survival and actionable targets for treatment [abstract]. Cancer Immunol Res. 2020;8(4 Suppl):B63.
  21. Zhou Q, Vadakekolathu J, Sharif K, Russell T, Rowe H, Millner P, et al. THU0028 An explanation for how viral infection may trigger spondyloarthropathy based on TLR9 driven TNF responses from entheseal derived plasmacytoid dendritic cells [abstract]. Ann Rheum Dis. 2020;79(Suppl 1):227-8.
  22. Vadakekolathu J, Lai C, Reeder S, Church SE, Hood T, Muth J, et al. Abstract CT035: TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia [abstract]. Cancer Res. 2020;80(16 Suppl):CT035.
  23. Vadakekolathu J, Yau TO, Church SE, Rettig MP, Aldoss I, Uy GL, et al. Immune senescence and exhaustion correlate with response to flotetuzumab, an investigational CD123×CD3 bispecific DART® molecule, in acute myeloid leukemia [abstract]. Blood. 2020;136(Suppl 1):26-8.
  24. Vadakekolathu J, Yau TO, Altmann H, Church SE, Knaus HA, Minden MD, et al. An immune senescence and exhaustion-related RNA profile predicts clinical outcomes in acute myeloid leukemia [abstract]. Blood. 2020;136(Suppl 1):26-7.
  25. Lai C, Vadakekolathu J, Reeder S, Church SE, Ballesteros-Merino C, Aldoss I, et al. TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia [abstract]. Blood. 2020;136(Suppl 1):3-4.
  26. Le Vu P, Vadakekolathu J, Christensen D, Durrant L, Pockley G, McArdle SE. Abstract B118: Development of a novel prostatic acid phosphatase-derived vaccine for the treatment of advanced prostate cancer [abstract]. Cancer Immunol Res. 2019;7(2 Suppl):B118.
  27. Di Biase A, Regad T, Vadakekolathu J, Powe D, Jäck HM, Roth E. Abstract B152: Generation of monoclonal antibodies against a newly identified target for invasive prostate cancer and their use in the development of an antibody-based targeting therapy [abstract]. Cancer Immunol Res. 2019;7(2 Suppl):B152.
  28. Alves RS, McArdle SE, Vadakekolathu J, Gonçalves AC, Freitas-Tavares P, Pereira A, et al. PF401 Immune system and chronic myeloid leukemia: the impact of tyrosine kinase inhibitors [abstract]. HemaSphere. 2019;3(S1):152-3.
  29. Rutella S, Church SE, Vadakekolathu J, Reeder S, Sullivan AH, Warren S, et al. Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA) [abstract]. Ann Oncol. 2019;30(Suppl 5):v38-9.
  30. Park H, Uronis H, Kang Y-K, Ng MCH, Enzinger P, Lee KW, …, Vadakekolathu J, et al. Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T) [abstract]. Ann Oncol. 2019;30(Suppl 5):v485.
  31. Vadakekolathu J, Reeder S, Coveney C, Rutella S. Tipifarnib modulates interferon (IFN)-γ-Inducible genes in acute myeloid leukemia [abstract]. Blood. 2019;134(Suppl 1):2726.
  32. Ciciarello M, Corradi G, Sangaletti S, Bassani B, Simonetti G, Vadakekolathu J, et al. Interferon-γ-dependent inflammatory signature in acute myeloid leukemia cells is able to shape stromal and immune bone marrow microenvironment [abstract]. Blood. 2019;134(Suppl 1):1212.
  33. Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, et al. Immune landscapes predict chemotherapy resistance and anti-leukemic activity of flotetuzumab, an investigational CD123×CD3 bispecific DART® molecule, in patients with relapsed/refractory acute myeloid leukemia [abstract]. Blood. 2019;134(Suppl 1):460.

See all of Jayakumar Vadakekolathu's publications...